Sign in
Taking peoplePhase 1/2

Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Key facts

Who runs it
Yan Hongli
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
50 people, planned
Started
15 Oct 2024
Planned end
30 Mar 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Climen 21 Tablets
  • hA-MSCs
Record updated
11 August 2025

Who can take part

Age
20 years to 40 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • The intention of pregnant women aged >= 20 and < 40, with normal karyotype
  • Oligo/amenorrhea for at least 4 months
  • Elevated FSH level >25 IU/l on two occasions >4 weeks apart
  • Without a history of stem cell therapy and no growth hormone and/or estrogen and progesterone therapy within the previous 3 months
  • Voluntary participation in the study with signed informed consent

Who cannot take part

  • Genetic diseases, chromosomal abnormalities, and genetic deficiency that clearly cause premature ovarian insufficiency/premature ovarian failure
  • With breast, uterine, ovarian tumors, or any other benign or malignant tumors
  • Allergic history to drugs or any other things
  • Presence of genetic disorders such as Turner's syndrome, congenital malformations of the reproductive organs
  • Have undergone ovariectomy or have organic gynaecological diseases
  • Presence of other gynaecological endocrine diseases such as polycystic ovary syndrome
  • Severe functional impairment of vital organs
  • High risk factors for venous thromboembolism and abnormalities in coagulation mechanisms
  • Unable to follow the treatment observation process required by the trial
  • Attending doctor considers inappropriate to take part in

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 20 and 40 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.

The 2 groups in the trial

  • ClimenExisting treatment, for comparison

    Hormone replacement therapy (HRT): Take the drug Climen. Each box has 21 tablets. The first 11 tablets contain 2 milligrams of estradiol valerate each. The last 10 tablets contain 2 milligrams of estradiol valerate and 1 milligram of cyproterone acetate each. Begin taking it on the fifth day of your menstrual cycle. Take one tablet every day for seven days. Then, stop taking the medicine for seven days. After that, continue for two cycles in a row.

    Treatment: Climen 21 Tablets

  • hA-MSCs+ClimenTreatment being tested

    The stem cell treatment group will be administered Climen, with the dosage and method of administration to be determined based on the control group. Concurrently, patients will receive the initial infusion of amniotic MSCs intravenously on the third day after the onset of menstruation, with a subsequent infusion administered after one month. The number of stem cells infused was calculated according to 1 million cells per kilogram of body weight.

    Treatment: Climen 21 Tablets and hA-MSCs

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open-label, Parallel-controlled Clinical Study of Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
Criteria questions
Built from NCT07115082, who can take part
Record updated
11 August 2025